ResTORbio Announces Phase 2b Human Trial Results
It has been demonstrated that TORC1 inhibition increases lifespan.
We are happy to announce today that results from a human study targeting the aging immune systems have been published. An immune system-boosting medication appears to be effective.
To boost immunity, target TORC1
As we age, our immune system becomes weaker and less able to detect and combat infections. The elderly can be more susceptible to respiratory tract infection (RTIs), which could negatively impact their health, quality of life, and even put them at risk for death. There are no RTI treatments that directly target the aging immunity system.
Source:
https://www.leafscience.org/restorbio-announces-results-in-phase-2b-human-trial/
